Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyuki Hata

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Internal Medicine (Tokyo, Japan)|September 16, 2016
Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomide, Cyclophosphamide, and DexamethasoneYoshitaka Kikukawa, Hiroyuki Hata, Mitsuharu Ueda, et al.
Systematic and Applied Microbiology|July 21, 2007
Mycobacterium species identification--a new approach via dnaJ gene sequencingMakiko Yamada-Noda, Kiyofumi Ohkusu, Hiroyuki Hata, et al.
Internal Medicine (Tokyo, Japan)|November 3, 2017
Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in JapanChihiro Shimazaki, Hiroyuki Hata, Sinsuke Iida, et al.
Molecular Cancer Therapeutics|July 16, 2005
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent mannerHiro Tatetsu, Yutaka Okuno, Miki Nakamura, et al.
Internal Medicine (Tokyo, Japan)|February 14, 2018
Pancytopenia and Myelodysplastic Changes in Aceruloplasminemia: A Case with a Novel Pathogenic Variant in the Ceruloplasmin GeneAyako Yamamura, Yoshitaka Kikukawa, Kenji Tokunaga, et al.
Experimental Hematology & Oncology|April 25, 2015
Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1Shiho Fujiwara, Naoko Wada, Yawara Kawano, et al.
Biochemical and Biophysical Research Communications|March 29, 2017
A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivoNao Nishimura, Shinya Endo, Shikiko Ueno, et al.
International Journal of Hematology|March 17, 2016
Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroidsShiho Fujiwara, Hiromi Mochinaga, Hirotomo Nakata, et al.
Oncology Letters|April 5, 2018
Bufalin induces DNA damage response under hypoxic condition in myeloma cellsEri Fujii, Yuki Inada, Misaki Kakoki, et al.
International Journal of Oncology|July 7, 2012
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomideYawara Kawano, Shiho Fujiwara, Naoko Wada, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Internal Medicine (Tokyo, Japan)|September 16, 2016
Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomide, Cyclophosphamide, and DexamethasoneYoshitaka Kikukawa, Hiroyuki Hata, Mitsuharu Ueda, et al.
Systematic and Applied Microbiology|July 21, 2007
Mycobacterium species identification--a new approach via dnaJ gene sequencingMakiko Yamada-Noda, Kiyofumi Ohkusu, Hiroyuki Hata, et al.
Internal Medicine (Tokyo, Japan)|November 3, 2017
Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in JapanChihiro Shimazaki, Hiroyuki Hata, Sinsuke Iida, et al.
Molecular Cancer Therapeutics|July 16, 2005
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent mannerHiro Tatetsu, Yutaka Okuno, Miki Nakamura, et al.
Internal Medicine (Tokyo, Japan)|February 14, 2018
Pancytopenia and Myelodysplastic Changes in Aceruloplasminemia: A Case with a Novel Pathogenic Variant in the Ceruloplasmin GeneAyako Yamamura, Yoshitaka Kikukawa, Kenji Tokunaga, et al.
Experimental Hematology & Oncology|April 25, 2015
Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1Shiho Fujiwara, Naoko Wada, Yawara Kawano, et al.
Biochemical and Biophysical Research Communications|March 29, 2017
A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivoNao Nishimura, Shinya Endo, Shikiko Ueno, et al.
International Journal of Hematology|March 17, 2016
Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroidsShiho Fujiwara, Hiromi Mochinaga, Hirotomo Nakata, et al.
Oncology Letters|April 5, 2018
Bufalin induces DNA damage response under hypoxic condition in myeloma cellsEri Fujii, Yuki Inada, Misaki Kakoki, et al.
International Journal of Oncology|July 7, 2012
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomideYawara Kawano, Shiho Fujiwara, Naoko Wada, et al.
Pageof 7